טוען...
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade in Solid Malignancies
There have been unprecedented advances in the treatment of cancer through the use of immunotherapy, with several agents now FDA-approved for use in widespread metastatic disease across cancer types. Immune checkpoint blockade represents a particularly promising class of agents that block inhibitory...
שמור ב:
| הוצא לאור ב: | Ann Surg Oncol |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6105272/ https://ncbi.nlm.nih.gov/pubmed/29500764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-018-6379-8 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|